Redmile Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

Redmile Group’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,500	Closed	-$409K	–	64
2015 Q3	$409K	Hold	6,500	–	–	0.03%	52
2015 Q2	$460K	Hold	6,500	–	–	0.04%	55
2015 Q1	$457K	Hold	6,500	–	–	0.04%	51
2014 Q4	$418K	Hold	6,500	–	–	0.05%	48
2014 Q3	$413K	Hold	6,500	–	–	0.05%	53
2014 Q2	$403K	Hold	6,500	–	–	0.05%	43
2014 Q1	$379K	Hold	6,500	–	–	0.05%	51
2013 Q4	$345K	Hold	6,500	–	–	0.04%	50
2013 Q3	$311K	Hold	6,500	–	–	0.05%	46
2013 Q2	$296K	Buy	+6,500	New	+$301K	0.05%	42

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Redmile Group's PPH Position: Q4 2015 in Review

Redmile Group sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2015, closing a stake of 6,500 shares — an estimated $409K sold.

Redmile Group first reported a position in PPH in Q2 2013 and held it in 10 quarters. The position peaked at $460K in Q2 2015. 59 funds tracked by Wall St. Rank hold PPH as of Q4 2015.

Redmile Group reported no remaining VanEck Pharmaceutical ETF position as of Q4 2015 after selling out during the quarter.
Redmile Group sold 6,500 VanEck Pharmaceutical ETF shares in Q4 2015, an estimated $409K.
Redmile Group first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 10 quarters.
Redmile Group's VanEck Pharmaceutical ETF position peaked at $460K in Q2 2015.
59 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2015.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.